Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...
Lilly inks a global licensing deal with OliX for OLX75016, a Phase 1 candidate targeting MASH and other cardiometabolic conditions. Get access to your new suite of high-powered trading tools ...
OliX Pharmaceuticals, the first Asian company to advance its own proprietary RNA interference (RNAi) technology platform into the clinic, is using RNAi technology to treat skin, eye and lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback